Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Highlights Late-Stage R&D Prospects Across Pharma Division

Executive Summary

J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.

You may also be interested in...



J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

In A Competitive New Cancer Field, Infinity Looks For A Place To Play

Infinity presented positive efficacy data on its oral PI3 kinase inhibitor IPI-145 in CLL and lymphoma at ASCO, but other drug makers also released strong data on potential competitors that are further ahead in clinical development, sparking a stock sell off.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel